Glenmark Pharma may move upto Rs 600: Abhishek Karande

Abhishek Karande of SBI Capital Securities told CNBC-TV18, "Glenmark Pharma will see an initial run up till Rs 600. It has been in consolidation for almost like more than two months. So I feel we are in a mode of a completion of this correction and then one can see an initial leg of move till Rs 600 mark."

The company's trailing 12-month (TTM) EPS was at Rs 16.57 per share. The stock's price-to-earnings (P/E) ratio was 32.75. The latest book value of the company is Rs 93.06 per share. At current value, the price-to-book value of the company was 5.83. The dividend yield of the company was 0.37 percent.

The stock's price-to-earnings (P/E) ratio stands at 32.71 on (NSE)

Disclosure: The stock discussed may have been recommended to his clients.